Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited)

v3.22.2.2
Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock Payable [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Mar. 31, 2021 $ 500 $ 56,075 $ 56,649,491 $ 136,000 $ (53,683,268) $ (87,830) $ 3,070,969
Beginning balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Beneficial conversion feature related to the Series E Preferred Shares 3,269,505 3,269,505
Amortization of beneficial conversion feature related to Series E Preferred Shares (817,376) (817,376)
Common stock vested to consultants 13 48,738 24,900 73,651
Net loss             (2,562,743)   (2,562,743)
Issuance of common stock upon conversion $ 133 421,353 421,486
Issuance of common stock upon conversion, shares     1,329,246            
Conversion of Series B PS to common stock $ 314 (314)
Conversion of Series B PS to common stock, shares   (262) 3,144,000            
Conversion of Series D PS to common stock $ 43 (43)
Conversion of Series D PS to common stock, shares     428,572            
Exchange of Series D PS to Series E PS (3,258,189) (3,258,189)
Sale of common shares and warrants for cash, less offering costs and commitment shares $ 3,577 17,273,546 17,277,123
Sale of common shares and warrants for cash, less offering costs and commitment shares, shares     35,772,729            
Exercise of warrants related to the sale of common shares $ 110 10,890 11,000
Exercise of warrants related to the sale of common shares, shares     1,100,000            
Redemption of Series D Preferred shares (2,534,758) (2,534,758)
Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity (3,087,830) 2,000,000 87,830 (1,000,000)
Common shares to be issued for Patent acquisition 5,000,000 5,000,000
Common stock vested to consultants, shares     125,000            
Ending balance, value at Jun. 30, 2021 $ 500 $ 60,132 74,163,982 7,160,900 (62,856,334) 18,950,668
Ending balance, shares at Jun. 30, 2021 5,000,000 345 601,315,481            
Beginning balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650 (150,036,023) (33,133,766)
Beginning balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Common stock issued for legal settlement to NSH shareholders $ 6,112 19,311,486 (19,317,598)
Common stock issued for legal settlement to NSH shareholders, shares     61,154,136            
Conversion of Series E PS to common stock $ 454 839,546 840,000
Conversion of Series E PS to common stock, shares     4,537,240            
Beneficial conversion feature related to the Series E Preferred Shares 99,000 (99,000)
Amortization of beneficial conversion feature related to Series E Preferred Shares (42,500) (42,500)
Accretion of Series E Preferred Shares (278,500) (278,500)
Dividends payable on Preferred Shares (102,227) (102,227)
Common stock issued in business agreement, to be paid from revenue earned $ 25 56,225 (56,250)
Common stock issued in business agreement, to be paid from revenue earned, shares     250,000            
Common stock vested to consultants $ 6 24,369 24,375
Net loss             (2,200,176)   (2,200,176)
Ending balance, value at Jun. 30, 2022 $ 500 $ 74,097 $ 117,032,233 $ 815,052 $ (56,250) $ (152,758,426) $ (34,892,794)
Ending balance, shares at Jun. 30, 2022 5,000,000 740,585,500